Insights / Health
The Promise of Outcomes-Based Agreements for Cell and Gene Therapies
There is a pressing need for pharma and biotech manufacturers to find cost-effective ways to help more patients gain access to cell and gene therapies. While many types of innovative payment models exist, outcomes-based agreements are emerging as an attractive best practice option for both manufacturers and payers.